• Optiscan launched InSpecta device in US
• Australian Breast Cancer Study advanced
• Received $2.537m in government grants
• Invested $1.936m in R&D
• Advanced clinical studies for US FDA submissions

Optiscan Imaging Ltd reported significant progress in the June 2026 quarter, highlighted by the successful commercial launch of its InSpecta device in the US and the advancement of multiple clinical studies. The company also received $2.537 million in government grants and tax incentives, including $0.843 million for developing its Edge-AI-enabled gastrointestinal flexible endomicroscope. Additionally, Optiscan invested $1.936 million in research and development to support planned US FDA submissions for its InVue and InForm devices in the second half of 2026. The Australian Breast Cancer Study utilizing the InVue and InForm platforms has advanced beyond the halfway mark, with promising interim imaging results across healthy and malignant breast tissue.

Optiscan is on track to submit FDA dossiers for InVue and InForm in the second half of 2026, with clinical studies progressing well.